Exact Mass: 428.2910548
Exact Mass Matches: 428.2910548
Found 500 metabolites which its exact mass value is equals to given mass value 428.2910548,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Primolut depot
CONFIDENCE standard compound; INTERNAL_ID 655; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10390; ORIGINAL_PRECURSOR_SCAN_NO 10389 CONFIDENCE standard compound; INTERNAL_ID 655; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10271; ORIGINAL_PRECURSOR_SCAN_NO 10269 CONFIDENCE standard compound; INTERNAL_ID 655; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10375; ORIGINAL_PRECURSOR_SCAN_NO 10374 CONFIDENCE standard compound; INTERNAL_ID 655; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10383; ORIGINAL_PRECURSOR_SCAN_NO 10381 CONFIDENCE standard compound; INTERNAL_ID 655; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10318; ORIGINAL_PRECURSOR_SCAN_NO 10317 CONFIDENCE standard compound; INTERNAL_ID 655; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10339; ORIGINAL_PRECURSOR_SCAN_NO 10337 D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D011372 - Progestins C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone
4,4-Diapolycopenedial
12-epi-Scalaradial
Nonaethylene glycol monomethyl ether
C19H40O10 (428.26213400000006)
Sorbitan oleate
Sorbitan oleate is an emulsifier and clarification agent in food preparations (sugar liquor or juice Emulsifier and clarification agent in food preparations (sugar liquor or juice) D013501 - Surface-Active Agents
25-Hydroxyvitamin D3-26,23-lactone
This compound belongs to the family of Sesterterpene Lactones. These are sesterterpenes containing a lactone ring
Spirostane-3,6-dione
Spirostane-3,6-dione is found in fruits. Spirostane-3,6-dione is isolated from fruits of Solanum torvum (pea eggplant). Isolated from fruits of Solanum torvum (pea eggplant). Spirostane-3,6-dione is found in fruits.
Glyceryl lactooleate
Glyceryl lactooleate is used as a food additive [EAFUS] ("EAFUS: Everything Added to Food in the United States. [http://www.eafus.com/]") It is used as a food additive .
Schidigeragenin B
Schidigeragenin B is found in fruits. Genin from Yucca schidigera (Mojave yucca
[(8R,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] hexanoate
Calcifediol lactone
Triheptanoin
A - Alimentary tract and metabolism > A16 - Other alimentary tract and metabolism products > A16A - Other alimentary tract and metabolism products > A16AX - Various alimentary tract and metabolism products
MG(PGF2alpha/0:0/0:0)
MG(PGF2alpha/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(PGE1/0:0/0:0)
MG(PGE1/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(PGD1/0:0/0:0)
MG(PGD1/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/PGF2alpha/0:0)
MG(0:0/PGF2alpha/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/PGE1/0:0)
MG(0:0/PGE1/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/PGD1/0:0)
MG(0:0/PGD1/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
3-Oxo-21α-methoxy-24,25,26,27-tetranortirucall-7-ene-23(21)-lactone
Neoruscogenin
Neoruscogenin is a natural product found in Helleborus orientalis with data available. Neoruscogenin, a member of the steroidal sapogenin family, is a bioavailable, potent, and high-affinity agonist of the nuclear receptor RORα (NR1F1)[1]. Neoruscogenin, a member of the steroidal sapogenin family, is a bioavailable, potent, and high-affinity agonist of the nuclear receptor RORα (NR1F1)[1].
13-(6-hydroxy-2,8-dimethyl-3,4-dihydrochromen-2-yl)-2,6,10-trimethyltrideca-2,6,10-triene-4,5-diol
Fluvirucin A1
A lactam that is 4-hydroxyazacyclotetradecan-2-one substituted by an ethyl group at position 11, methyl groups at position 3 and 7 and a 3-amino-3,6-dideoxy-alpha-L-talopyranosyl moiety at position 4 via a glycosyl linkage (the 3R,4S,7R,11S stereoisomer). It is isolated from the fermentation broth of an unidentified actinomycete species and exhibits potent inhibitory activity against influenza A virus. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
Triheptanoin
A - Alimentary tract and metabolism > A16 - Other alimentary tract and metabolism products > A16A - Other alimentary tract and metabolism products > A16AX - Various alimentary tract and metabolism products
(2E,6E)-2-(10(S),11(S)-dihydroxygeranylgeranyl)-6-methyl-1,4-benzoquinone
3,6-Dihydroxy-2-(15-phenylpentadecanoyl)-2-cyclohexen-1-one
17-Hydroxy-2-(5-Hydoxy-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-6-methyl-1,2-benzendiol|2-((2E,6E,10E,14Z)-5-hydroxy-15-hydroxymethyl-3,7,11-trimethylhexadeca-2,6,10,14-tetraenyl)-6-methylhydroquinone|2-<(2E,6E,10E,14Z)-5-hydroxy-15-hydroxymethyl-3,7,11-trimethylhexadeca-2,6,10,14-tetraenyl>-6-methylhydroquinone|2-[(2E,6E,10E,14Z)-5-hydroxy-15-hydroxymethyl-3,7,11-trimethylhexadeca-2,6,10,14-tetraenyl]-6-methylhydroquinone
(25R)-3beta-Hydroxy-5alpha-spirost-9(11)-en-12-on|(25R)-3beta-hydroxy-5alpha-spirost-9(11)-en-12-one|3beta-hydroxy-9(11)-en-12-oxo-(25R)-5alpha-spirostane|9(11)-dehydrohecogenin|9-dehydrohecogenin|Delta9(11)-22-isoallospirosten-3beta-ol-12-one|Delta9(11)-hecogenin
(25R)-17-Hydroxy-spirost-4-en-3-on|(25R)-17-hydroxy-spirost-4-en-3-one|(25R)-17alpha-hydroxyspirost-4-en-3-one|diosbulbisin A
3beta-Acetamido-18-methoxy-20-N-acetylconan-5-en
C26H40N2O3 (428.30387700000006)
4-hydroxy-3-(((1R,4aR,5S,6S,8aR)-6-hydroxy-5,8a-dimethyl-2-methylene-5-(4-methylpent-3-enyl)-decahydronaphthalen-1-yl)-methyl)-5,6-dimethyl-2H-pyran-2-one|BR-050
2-((2E,6E)-5-hydroxy-3,7,11,15-tetramethyl-12-oxohexadeca-2,6,14-trienyl)-6-methylhydroquinol|2-<(2E,6E)-5-hydroxy-3,7,11,15-tetramethyl-12-oxohexadeca-2,6,14-trienyl>-6-methylhydroquinol
(5alpha,12beta,17beta)-12-hydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-2-methyl-5-oxo-2,5-dihydrofuran-2-yl]gonan-3-one|cylindrictone B
4,4,14-trimethyl-3,7,15-trimethyl-3,7-dioxochol-8-en-24-oic acid|4,4,14-trimethyl-3,7-dioxochol-8-en-24-oic acid|4,4,14alpha-trimethyl-3,7-dioxo-5alpha-chol-8-en-24-oic acid
20S,24-epoxy-25,26,27-trisnor-24-oxo-3,4-seco-dammar-4(28),22-dien-3-oic acid
3-Oxo-21|A-methoxy-24,25,26,27-tetranortirucall-7-ene-23(21)-lactone
(2R)-2,8-dimethyl-2-[(3E,7E)-4,8-dimethyl-13-hydroxy-12-hydroxymethyldeca-3,7,11-trienyl]chroman-6-ol|delta-amplexichromanol
erythro-23-O-methylneocyclocitrinol|threo-23-O-methylneocyclocitrinol
15alpha-hydroxy-3-oxo-5alpha-lanosta-7,9(11)-dien-24-oic acid|ganoderic acid Jd
3beta,11alpha-dihydroxyspirosta-5,25(27)-diene|spirost-5,25(27)-diene-3beta,11alpha-diol
(16beta,22E)-16,18,20-Trihydroxycholesta-1,4,22-trien-3-one|(20S,22E)-cholesta-1,4,22-triene-16beta,18,20-triol-3-one
MLS001148643-01!17ALPHA-HYDROXYPROGESTERONE CAPROATE630-56-8
Sorbitane Monooleate - Polysorbate 80 in-source fragment
C27H40O4_(3beta,5alpha,8xi,14xi,25S)-3-Hydroxyspirost-9(11)-en-12-one
Ala Ile Ile Ile
C21H40N4O5 (428.29985500000004)
Ala Ile Ile Leu
C21H40N4O5 (428.29985500000004)
Ala Ile Leu Ile
C21H40N4O5 (428.29985500000004)
Ala Ile Leu Leu
C21H40N4O5 (428.29985500000004)
Ala Leu Ile Ile
C21H40N4O5 (428.29985500000004)
Ala Leu Ile Leu
C21H40N4O5 (428.29985500000004)
Ala Leu Leu Ile
C21H40N4O5 (428.29985500000004)
Ala Leu Leu Leu
C21H40N4O5 (428.29985500000004)
Gly Lys Lys Pro
Gly Lys Pro Lys
Gly Pro Lys Lys
Ile Ala Ile Ile
C21H40N4O5 (428.29985500000004)
Ile Ala Ile Leu
C21H40N4O5 (428.29985500000004)
Ile Ala Leu Ile
C21H40N4O5 (428.29985500000004)
Ile Ala Leu Leu
C21H40N4O5 (428.29985500000004)
Ile Ile Ala Ile
C21H40N4O5 (428.29985500000004)
Ile Ile Ala Leu
C21H40N4O5 (428.29985500000004)
Ile Ile Ile Ala
C21H40N4O5 (428.29985500000004)
Ile Ile Leu Ala
C21H40N4O5 (428.29985500000004)
Ile Ile Pro Ser
Ile Ile Ser Pro
Ile Leu Ala Ile
C21H40N4O5 (428.29985500000004)
Ile Leu Ala Leu
C21H40N4O5 (428.29985500000004)
Ile Leu Ile Ala
C21H40N4O5 (428.29985500000004)
Ile Leu Leu Ala
C21H40N4O5 (428.29985500000004)
Ile Leu Pro Ser
Ile Leu Ser Pro
Ile Pro Ile Ser
Ile Pro Leu Ser
Ile Pro Ser Ile
Ile Pro Ser Leu
Ile Pro Thr Val
Ile Pro Val Thr
Ile Ser Ile Pro
Ile Ser Leu Pro
Ile Ser Pro Ile
Ile Ser Pro Leu
Ile Thr Pro Val
Ile Thr Val Pro
Ile Val Pro Thr
Ile Val Thr Pro
Ile Val Val Val
C21H40N4O5 (428.29985500000004)
Lys Gly Lys Pro
Lys Gly Pro Lys
Lys Lys Gly Pro
Lys Lys Pro Gly
Lys Pro Gly Lys
Lys Pro Lys Gly
Leu Ala Ile Ile
C21H40N4O5 (428.29985500000004)
Leu Ala Ile Leu
C21H40N4O5 (428.29985500000004)
Leu Ala Leu Ile
C21H40N4O5 (428.29985500000004)
Leu Ala Leu Leu
C21H40N4O5 (428.29985500000004)
Leu Ile Ala Ile
C21H40N4O5 (428.29985500000004)
Leu Ile Ala Leu
C21H40N4O5 (428.29985500000004)
Leu Ile Ile Ala
C21H40N4O5 (428.29985500000004)
Leu Ile Leu Ala
C21H40N4O5 (428.29985500000004)
Leu Ile Pro Ser
Leu Ile Ser Pro
Leu Leu Ala Ile
C21H40N4O5 (428.29985500000004)
Leu Leu Ala Leu
C21H40N4O5 (428.29985500000004)
Leu Leu Ile Ala
C21H40N4O5 (428.29985500000004)
Leu Leu Leu Ala
C21H40N4O5 (428.29985500000004)
Leu Leu Pro Ser
Leu Leu Ser Pro
Leu Pro Ile Ser
Leu Pro Leu Ser
Leu Pro Ser Ile
Leu Pro Ser Leu
Leu Pro Thr Val
Leu Pro Val Thr
Leu Ser Ile Pro
Leu Ser Leu Pro
Leu Ser Pro Ile
Leu Ser Pro Leu
Leu Thr Pro Val
Leu Thr Val Pro
Leu Val Pro Thr
Leu Val Thr Pro
Leu Val Val Val
C21H40N4O5 (428.29985500000004)
Pro Gly Lys Lys
Pro Ile Ile Ser
Pro Ile Leu Ser
Pro Ile Ser Ile
Pro Ile Ser Leu
Pro Ile Thr Val
Pro Ile Val Thr
Pro Lys Gly Lys
Pro Lys Lys Gly
Pro Leu Ile Ser
Pro Leu Leu Ser
Pro Leu Ser Ile
Pro Leu Ser Leu
Pro Leu Thr Val
Pro Leu Val Thr
Pro Ser Ile Ile
Pro Ser Ile Leu
Pro Ser Leu Ile
Pro Ser Leu Leu
Pro Thr Ile Val
Pro Thr Leu Val
Pro Thr Val Ile
Pro Thr Val Leu
Pro Val Ile Thr
Pro Val Leu Thr
Pro Val Thr Ile
Pro Val Thr Leu
Ser Ile Ile Pro
Ser Ile Leu Pro
Ser Ile Pro Ile
Ser Ile Pro Leu
Ser Leu Ile Pro
Ser Leu Leu Pro
Ser Leu Pro Ile
Ser Leu Pro Leu
Ser Pro Ile Ile
Ser Pro Ile Leu
Ser Pro Leu Ile
Ser Pro Leu Leu
Thr Ile Pro Val
Thr Ile Val Pro
Thr Leu Pro Val
Thr Leu Val Pro
Thr Pro Ile Val
Thr Pro Leu Val
Thr Pro Val Ile
Thr Pro Val Leu
Thr Val Ile Pro
Thr Val Leu Pro
Thr Val Pro Ile
Thr Val Pro Leu
Val Ile Pro Thr
Val Ile Thr Pro
Val Ile Val Val
C21H40N4O5 (428.29985500000004)
Val Leu Pro Thr
Val Leu Thr Pro
Val Leu Val Val
C21H40N4O5 (428.29985500000004)
Val Pro Ile Thr
Val Pro Leu Thr
Val Pro Thr Ile
Val Pro Thr Leu
Val Thr Ile Pro
Val Thr Leu Pro
Val Thr Pro Ile
Val Thr Pro Leu
Val Val Ile Val
C21H40N4O5 (428.29985500000004)
Val Val Leu Val
C21H40N4O5 (428.29985500000004)
Val Val Val Ile
C21H40N4O5 (428.29985500000004)
Val Val Val Leu
C21H40N4O5 (428.29985500000004)
(23R,25R)-25-hydroxyvitamin D3 26,23-lactone / (23R,25R)-25-hydroxycholecalciferol 26,23-lactone
(23S,25R)-25-hydroxyvitamin D3 26,23-lactone / (23S,25R)-25-hydroxycholecalciferol 26,23-lactone
(23R,25S)-25-hydroxyvitamin D3 26,23-lactone / (23R,25S)-25-hydroxycholecalciferol 26,23-lactone
(23S,25S)-25-hydroxyvitamin D3 26,23-lactone / (23S,25S)-25-hydroxycholecalciferol 26,23-lactone
(5Z,7E,22E)-(1S,3R,24R,25R)-25,26-epoxy-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,24-triol
(5Z,7E,22E)-(1S,3R,24S,25S)-25,26-epoxy-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,24-triol
1,25-Dihydroxy-24-oxo-16-ene-vitamin D3
D018977 - Micronutrients > D014815 - Vitamins > D004100 - Dihydroxycholecalciferols D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols
Arlacel
D013501 - Surface-Active Agents
Schidigeragenin B
Chlorogenone
Sorbitan oleate
D013501 - Surface-Active Agents
ascr#31
An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E,17R)-17-hydroxyoctadec-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.
oscr#31
An omega-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E)-18-hydroxyoctadec-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.
(23S,25R)-25-hydroxyvitamin D3 26,23-lactone
(22E)-(24R,25R)-25,26-epoxy-1alpha,24-dihydroxy-22,23-didehydrovitamin D3
(22E)-(24S,25S)-25,26-epoxy-1alpha,24-dihydroxy-22,23-didehydrovitamin D3
1,3-Di(1-adamantyl)imidazolinium Tetrafluoroborate
C23H37BF4N2 (428.29857599999997)
1,4,8,11-Tetrakis(aminocarbonylmethyl)-1,4,8,11-tetraazacyclotetradecane
5-(3,5-dimethyl-4-octoxyphenyl)-3-hexylthiophene-2-carbaldehyde
C27H40O2S (428.27488600000004)
Umeclidinium
C29H34NO2+ (428.25894040000003)
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent
Scalaradial
A scalarane sesterterpenoid with formula C27H40O4. It is a natural product found in the marine sponges Spongia officinalis and Cacospongia mollior, and exhibits anti-inflammatory activity.
(2E)-18-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]octadec-2-enoic acid
(2E,17R)-17-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]octadec-2-enoic acid
[(8R,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] hexanoate
prostaglandin F2alpha 1-glyceryl ester
A 1-monoglyceride resulting from the condensation of the carboxy group of prostaglandin F2alpha with the 1-hydroxy group of glycerol.
(22E)-(24R,25R)-25,26-epoxy-1alpha,24-dihydroxy-22,23-didehydrovitamin D3/(22E)-(24R,25R)-25,26-epoxy-1alpha,24-dihydroxy-22,23-didehydrocholecalciferol
(6R)-6-[(8S,9S,10R,13R,14S,17R)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-methyl-3-oxoheptanoic acid
16-Hydroxy-7,9,13-trimethyl-5-methylidenespiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2-oxane]-10-one
3-hydroxy-5-[2-[(4Z)-4-[(2E)-2-(5-hydroxy-2-methylidenecyclohexylidene)ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]propyl]-3-methyloxolan-2-one
O-hexadecanedioyl-L-carnitine(1-)
C23H42NO6- (428.30119720000005)
A dicarboxylic acid monoanion that is the conjugate base of O-hexadecanedioyl-L-carnitine; major spoecies at pH 7.3.
1-[3-methyl-2-[[2-(methylamino)-1-oxopropyl]amino]-1-oxobutyl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-2-pyrrolidinecarboxamide
4-{[(4-Fluorophenyl)methyl]({[4-(2-methylpropoxy)phenyl]methyl}carbamoyl)amino}-1-methylpiperidin-1-ium
(5alpha,8xi,14xi,16xi,17xi)-3-Hydroxyspirost-9(11)-en-12-one
hydroxyprogesterone caproate
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D011372 - Progestins C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone
(all-E)-2,6,10,15,19,23-hexamethyltetracosa-2,4,6,8,10,12,14,16,18,20,22-undecaenedial
prostaglandin F2alpha 2-glyceryl ester
A 2-monoglyceride obtained by formal condensation of the carboxy group of prostaglandin F2alpha with the 2-hydroxy group of glycerol.
(1s,3as,3br,9ar,9bs,11as)-1-hydroxy-1-[(2r,3r,6r)-2-hydroxy-6-isopropyloxan-3-yl]-9a,11a-dimethyl-2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one
16'-hydroxy-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-11'-en-10'-one
13-hydroxy-5b,8,8,11a,13a-pentamethyl-4h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-chryseno[1,2-b]furan-4-yl acetate
(1's,2r,2's,4's,7's,8'r,9's,12's,13'r,14'r,16'r)-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-ene-14',16'-diol
(2's,4'ar,4'bs,7's,8'ar)-2',4'b,7,8',8',10'a-hexamethyl-2',3',4',4'a,5',6',7',8'a,9',10'-decahydro-3h-spiro[1-benzofuran-2,1'-phenanthrene]-4,5,7'-triol
2-[(2e,6e,10e,12s)-12-hydroxy-11-(hydroxymethyl)-3,7,15-trimethylhexadeca-2,6,10,14-tetraen-1-yl]-6-methylbenzene-1,4-diol
4-hydroxy-3-{[3-(hydroxymethyl)-3,3a,6,7,9a-pentamethyl-octahydro-1h-cyclopenta[a]naphthalen-6-yl]methyl}benzoic acid
(1'r,2r,2's,4's,5r,7's,8'r,9's,12's,13'r,18's)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-16',19'-dione
(4r,5ar,5br,7as,11as,11br,13r,13ar)-13-hydroxy-5b,8,8,11a,13a-pentamethyl-4h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-chryseno[1,2-b]furan-4-yl acetate
(4r,6r,7z,10e)-4-hydroxy-13-[(2r)-6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl]-2,6,10-trimethyltrideca-7,10-dien-5-one
(4r)-4-hydroxy-13-[(2r)-6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl]-2,6,10-trimethyltrideca-2,10-dien-5-one
(4r,6s,7z,10e)-4-hydroxy-13-[(2r)-6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl]-2,6,10-trimethyltrideca-7,10-dien-5-one
(4r)-4-[(1r,3ar,5ar,9as,11ar)-3a,6,6,9a,11a-pentamethyl-4,7-dioxo-1h,2h,3h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]pentanoic acid
n-[1-(2-benzyl-3-methoxy-4-methyl-5-oxo-2h-pyrrol-1-yl)-3-methyl-1-oxobutan-2-yl]-2-methylhexanimidic acid
(5s)-5-[(3r,8r,10s,11s,12s,15s,16r)-10-hydroxy-7,7,12,16-tetramethyl-6-oxopentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]-5-methyloxolan-2-one
(4as,4br,6s,6ar,7r,10as,10br,12as)-7,8-diformyl-1,1,4a,6a,10b-pentamethyl-2,3,4,4b,5,6,7,10,10a,11,12,12a-dodecahydrochrysen-6-yl acetate
(3e,5s,7s,20s)-20-[(2r,4r)-2,4-dihydroxypentyl]-5,7-dihydroxy-1-oxacycloicos-3-en-2-one
n-[(2r)-1-[(2s)-2-benzyl-3-methoxy-4-methyl-5-oxo-2h-pyrrol-1-yl]-3-methyl-1-oxobutan-2-yl]-2-methylhexanimidic acid
2-[(2e,6e,10e)-12-hydroxy-11-(hydroxymethyl)-3,7,15-trimethylhexadeca-2,6,10,14-tetraen-1-yl]-6-methylbenzene-1,4-diol
2,6,10,15,19,23-hexamethyltetracosa-2,4,6,8,10,12,14,16,18,20,22-undecaenedial
2-(10,11-dihydroxy-3,7,11,15-tetramethylhexadeca-2,6,14-trien-1-yl)-6-methylcyclohexa-2,5-diene-1,4-dione
(1s,5as,5br,7as,11as,11br,13as,13bs)-5b,8,8,11a,13a-pentamethyl-13-oxo-1h,3h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13bh-chryseno[1,2-c]furan-1-yl acetate
3-{[(3r,3ar,5as,6r,7r,9as,9br)-3-(hydroxymethyl)-3,3a,6,7,9a-pentamethyl-octahydro-1h-cyclopenta[a]naphthalen-6-yl]methyl}-4-hydroxybenzoic acid
4-hydroxy-1,11,14,18,18-pentamethyl-8-oxapentacyclo[11.8.0.0²,¹¹.0⁵,⁹.0¹⁴,¹⁹]henicosa-5(9),6-dien-10-yl acetate
3-epineoruscogenin
{"Ingredient_id": "HBIN008490","Ingredient_name": "3-epineoruscogenin","Alias": "NA","Ingredient_formula": "C27H40O4","Ingredient_Smile": "CC1C2C(CC3C2(CCC4C3CC=C5C4(C(CC(C5)O)O)C)C)OC16CCC(=C)CO6","Ingredient_weight": "428.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "6973","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "21626040","DrugBank_id": "NA"}
9(11)-dehydrohecogenin
{"Ingredient_id": "HBIN013967","Ingredient_name": "9(11)-dehydrohecogenin","Alias": "NA","Ingredient_formula": "C27H40O4","Ingredient_Smile": "CC1CCC2(C(C3C(O2)CC4C3(C(=O)C=C5C4CCC6C5(CCC(C6)O)C)C)C)OC1","Ingredient_weight": "428.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4927","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "15011079","DrugBank_id": "NA"}
2-[(2e,5r,6e,10e,14z)-5,16-dihydroxy-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]-6-methylbenzene-1,4-diol
(2s)-1-[(2s,5r)-5-[(2r)-1-ethoxy-1-oxopropan-2-yl]oxolan-2-yl]butan-2-yl (2s)-2-[(2s,5r)-5-[(2r)-2-hydroxypropyl]oxolan-2-yl]propanoate
5-[14-(3,5-dihydroxyphenyl)tetradecyl]-2-methylbenzene-1,3-diol
13-(6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl)-2,6,10-trimethyltrideca-2,6,10-triene-4,5-diol
(5as,5br,7as,11as,11br,13r,13as,13br)-5b,8,8,11a,13a-pentamethyl-3-oxo-1h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h,13bh-chryseno[1,2-c]furan-13-yl acetate
2-[(2e,6e,10s,11r)-10,11-dihydroxy-3,7,11,15-tetramethylhexadeca-2,6,14-trien-1-yl]-6-methylcyclohexa-2,5-diene-1,4-dione
(1's,2r,2's,4's,5r,7's,8'r,9's,13's,16's,18's)-16'-hydroxy-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-11'-en-10'-one
5b,8,8,11a,13a-pentamethyl-1-oxo-3h,4h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-chryseno[1,2-c]furan-13-yl acetate
2-[(3r,6r)-6-(8-hydroperoxy-4,8,12-trimethyltridec-11-en-1-yl)-6-methyl-1,2-dioxan-3-yl]propanoic acid
(4r,5as,5br,7as,11as,11br,13r,13ar)-13-hydroxy-5b,8,8,11a,13a-pentamethyl-4h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-chryseno[1,2-b]furan-4-yl acetate
(4r,10e)-4-hydroxy-13-[(2r)-6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl]-2,6,10-trimethyltrideca-7,10-dien-5-one
(4r,10e)-4-hydroxy-13-[(2r)-6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl]-2,6,10-trimethyltrideca-2,10-dien-5-one
2-hydroxy-1-(2-hydroxy-6-methylhept-3-en-2-yl)-11a-(hydroxymethyl)-9a-methyl-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one
3-(acetyloxy)-5-(heptadeca-8,11-dien-1-yl)phenyl acetate
7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-ene-11',16'-diol
(4r,7z,10e)-4-hydroxy-13-[(2r)-6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl]-2,6,10-trimethyltrideca-7,10-dien-5-one
5b,8,8,11a,13a-pentamethyl-3-oxo-1h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h,13bh-chryseno[1,2-c]furan-13-yl acetate
(6s)-6-[(1s)-1-[(1s,2r,5r,6r,9s,10s,11s)-10-hydroxy-2,6,10-trimethyl-11-(prop-1-en-2-yl)-14-oxatetracyclo[7.4.1.0¹,⁹.0²,⁶]tetradecan-5-yl]ethyl]-3-methyl-5,6-dihydropyran-2-one
3-(acetyloxy)-5-[(8z,11z)-heptadeca-8,11-dien-1-yl]phenyl acetate
(4r,5s)-13-[(2r)-6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl]-2,6,10-trimethyltrideca-2,6,10-triene-4,5-diol
3-{2-[(2r,4as,5r,8as)-2,4a-dimethyl-5-(4-methylpent-3-en-1-yl)-6-oxo-hexahydro-1h-naphthalen-2-yl]ethyl}-4-hydroxy-5,6-dimethylpyran-2-one
(1r,2s,3as,3br,9ar,9bs,11ar)-2-hydroxy-1-[(2s,3e)-2-hydroxy-6-methylhept-3-en-2-yl]-11a-(hydroxymethyl)-9a-methyl-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one
(4as,4br,8as,9r,10ar)-2-[(1r,2r)-2-hydroxy-4-methyl-5-oxocyclohex-3-en-1-yl]-4b,8,8,10a-tetramethyl-4,4a,5,6,7,8a,9,10-octahydro-1h-phenanthren-9-yl acetate
2-[(1z,3s,6e,9s,10e)-3,9-dihydroxy-3,7,11,15-tetramethylhexadeca-1,6,10,14-tetraen-1-yl]-5-methylbenzene-1,4-diol
7-hydroxy-3a,6,6,11a-tetramethyl-4-oxo-1-(4-oxopentan-2-yl)-1h,2h,3h,3bh,7h,8h,9h,9ah,10h,11h-cyclopenta[a]phenanthrene-9b-carbaldehyde
2',4'b,7,8',8',10'a-hexamethyl-2',3',4',4'a,5',6',7',8'a,9',10'-decahydro-3h-spiro[1-benzofuran-2,1'-phenanthrene]-4,5,7'-triol
(4ar,4br,6r,6as,7r,10ar,10bs,12ar)-7,8-diformyl-1,1,4a,6a,10b-pentamethyl-2,3,4,4b,5,6,7,10,10a,11,12,12a-dodecahydrochrysen-6-yl acetate
2-[(2e,6e,10e,14s)-14,15-dihydroxy-3,7,11,15-tetramethylhexadeca-2,6,10-trien-1-yl]-5-methylcyclohexa-2,5-diene-1,4-dione
(2s,2's,8'ar)-2',4'b,7,8',8',10'a-hexamethyl-2',3',4',4'a,5',6',7',8'a,9',10'-decahydro-3h-spiro[1-benzofuran-2,1'-phenanthrene]-4,5,7'-triol
2-(8,9-dihydroxy-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl)-6-methylbenzene-1,4-diol
(2r,9's,13's,18's)-16'-hydroxy-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-11'-en-10'-one
4-{3-hydroxy-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl}pentanoic acid
2-(14,15-dihydroxy-3,7,11,15-tetramethylhexadeca-2,6,10-trien-1-yl)-5-methylcyclohexa-2,5-diene-1,4-dione
3-{[(1r,4ar,5s,6r,8ar)-6-hydroxy-5,8a-dimethyl-2-methylidene-5-(4-methylpent-3-en-1-yl)-hexahydro-1h-naphthalen-1-yl]methyl}-4-hydroxy-5,6-dimethylpyran-2-one
(5s)-5-[(1r,3r,8r,10s,11s,12s,15s,16r)-10-hydroxy-7,7,12,16-tetramethyl-6-oxopentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]-5-methyloxolan-2-one
(4s,5as,5br,7as,11as,11br,13r,13as)-13-hydroxy-5b,8,8,11a,13a-pentamethyl-4h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-chryseno[1,2-c]furan-4-yl acetate
(3e,5r,6s,20s)-20-[(2r,4r)-2,4-dihydroxypentyl]-5,6-dihydroxy-1-oxacycloicos-3-en-2-one
(5as,5br,7as,11as,11br,13r,13as)-5b,8,8,11a,13a-pentamethyl-1-oxo-3h,4h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-chryseno[1,2-c]furan-13-yl acetate
2-(14,15-dihydroxy-3,7,11,15-tetramethylhexadeca-2,6,10-trien-1-yl)-6-methylcyclohexa-2,5-diene-1,4-dione
2-[(2e,6e,10s,11s)-10,11-dihydroxy-3,7,11,15-tetramethylhexadeca-2,6,14-trien-1-yl]-6-methylcyclohexa-2,5-diene-1,4-dione
16-(2,5-dihydroxy-3-methylphenyl)-2-hydroxy-2,6,10,14-tetramethylhexadeca-6,10,14-trien-3-one
(1'r,2r,2's,4's,5s,7's,8'r,9's,12's,13'r,18's)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-16',19'-dione
2-[(2e,6e,8s,9s,10e)-8,9-dihydroxy-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]-6-methylbenzene-1,4-diol
4-hydroxy-5b,8,8,11a,13a-pentamethyl-4h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-chryseno[1,2-c]furan-13-yl acetate
2-[12-hydroxy-11-(hydroxymethyl)-3,7,15-trimethylhexadeca-2,6,10,14-tetraen-1-yl]-6-methylbenzene-1,4-diol
(5as,5br,7as,11as,11br,13s,13as)-5b,8,8,11a,13a-pentamethyl-1-oxo-3h,4h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-chryseno[1,2-c]furan-13-yl acetate
6-{1-[10-hydroxy-2,6,10-trimethyl-11-(prop-1-en-2-yl)-14-oxatetracyclo[7.4.1.0¹,⁹.0²,⁶]tetradecan-5-yl]ethyl}-3-methyl-5,6-dihydropyran-2-one
3-{[(3s,3as,5as,6s,7s,9ar,9bs)-3-(hydroxymethyl)-3,3a,6,7,9a-pentamethyl-octahydro-1h-cyclopenta[a]naphthalen-6-yl]methyl}-4-hydroxybenzoic acid
(3e,5s,7s,20r,22r)-5,7,20-trihydroxy-22-[(2r)-2-hydroxypropyl]-1-oxacyclodocos-3-en-2-one
4-hydroxy-13-(6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl)-2,6,10-trimethyltrideca-2,10-dien-5-one
(1s,3as,3br,9ar,9bs,11ar)-1-[(2s)-2-hydroxy-6-methylheptan-2-yl]-11a-(hydroxymethyl)-9a-methyl-1h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-dione
3,6-dihydroxy-2-(15-phenylpentadecanoyl)cyclohex-2-en-1-one
7,8-diformyl-1,1,4a,6a,10b-pentamethyl-2,3,4,4b,5,6,7,10,10a,11,12,12a-dodecahydrochrysen-6-yl acetate
(1's,2r,2's,4's,7's,8'r,9's,11'r,12's,13'r,16's)-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-ene-11',16'-diol
4-hydroxy-3-{[6-hydroxy-5,8a-dimethyl-2-methylidene-5-(4-methylpent-3-en-1-yl)-hexahydro-1h-naphthalen-1-yl]methyl}-5,6-dimethylpyran-2-one
2-[(1e,3s,6e,9s,10e)-3,9-dihydroxy-3,7,11,15-tetramethylhexadeca-1,6,10,14-tetraen-1-yl]-5-methylbenzene-1,4-diol
(4s,5s)-4-[(1s,3as,5ar,9ar,9br,11as)-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,5h,5ah,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methoxyoxolan-2-one
8'-hydroxy-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-17'-en-16'-one
(1r,2s,4s,10s,11s,13r,14s,19s)-4-hydroxy-1,11,14,18,18-pentamethyl-8-oxapentacyclo[11.8.0.0²,¹¹.0⁵,⁹.0¹⁴,¹⁹]henicosa-5(9),6-dien-10-yl acetate
(4r,6s,10e)-4-hydroxy-13-[(2r)-6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl]-2,6,10-trimethyltrideca-2,10-dien-5-one
(1r,3as,3bs,7s,9ar,9br,11ar)-7-hydroxy-3a,6,6,11a-tetramethyl-4-oxo-1-[(2r)-4-oxopentan-2-yl]-1h,2h,3h,3bh,7h,8h,9h,9ah,10h,11h-cyclopenta[a]phenanthrene-9b-carbaldehyde
(1'r,2s,2'r,4'r,7'r,8's,9'r,12'r,13's,14's,16'r)-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-ene-14',16'-diol
4-hydroxy-5b,8,8,11a,13a-pentamethyl-4h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-chryseno[1,2-b]furan-13-yl acetate
13-hydroxy-5b,8,8,11a,13a-pentamethyl-4h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-chryseno[1,2-c]furan-4-yl acetate
17-(3,5-dihydroxyphenyl)heptadecane-6-sulfonic acid
C23H40O5S (428.25963100000007)
5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-16',19'-dione
2-[(3s,9s,10e)-3,9-dihydroxy-3,7,11,15-tetramethylhexadeca-1,6,10,14-tetraen-1-yl]-5-methylbenzene-1,4-diol
(2r,2'r,4's,7's,8'r,9's,13's)-16'-hydroxy-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-1'(12')-en-11'-one
(4r)-4-[(1r,3s,3ar,9as,11ar)-3-hydroxy-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]pentanoic acid
(1's,2r,2's,4's,7's,8'r,9's,12's,13'r,14'r,16's)-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-ene-14',16'-diol
(1r,3as,3bs,7s,9ar,9br,11ar)-7-hydroxy-3a,6,6,11a-tetramethyl-4-oxo-1-[(2s)-4-oxopentan-2-yl]-1h,2h,3h,3bh,7h,8h,9h,9ah,10h,11h-cyclopenta[a]phenanthrene-9b-carbaldehyde
5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-10',16'-dione
(4as,4br,6s,6as,7s,10as,10br,12as)-7,8-diformyl-1,1,4a,6a,10b-pentamethyl-2,3,4,4b,5,6,7,10,10a,11,12,12a-dodecahydrochrysen-6-yl acetate
(4as,4br,6r,6ar,7r,10as,10br,12as)-7,8-diformyl-1,1,4a,6a,10b-pentamethyl-2,3,4,4b,5,6,7,10,10a,11,12,12a-dodecahydrochrysen-6-yl acetate
(4s,5s,6e)-13-[(2r)-6-hydroxy-2,8-dimethyl-3,4-dihydro-1-benzopyran-2-yl]-2,6,10-trimethyltrideca-2,6,10-triene-4,5-diol
2-(3,9-dihydroxy-3,7,11,15-tetramethylhexadeca-1,6,10,14-tetraen-1-yl)-5-methylbenzene-1,4-diol
(5s)-5-[(1s,3r,8r,10s,11s,12s,15s,16r)-10-hydroxy-7,7,12,16-tetramethyl-6-oxopentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]-5-methyloxolan-2-one
(1's,2r,2's,4's,5r,7's,8'r,9's,12's,13's,18's)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-10',16'-dione
2-(5,16-dihydroxy-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl)-6-methylbenzene-1,4-diol
(1s,5ar,5bs,7as,11as,11br,13as,13br)-5b-formyl-8,8,11a,13a-tetramethyl-1h,4h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h,13bh-chryseno[1,2-c]furan-1-yl acetate
5-{10-hydroxy-7,7,12,16-tetramethyl-6-oxopentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl}-5-methyloxolan-2-one
(4bs,6as,10as,10bs)-3-(2-carboxyethyl)-2-(carboxymethyl)-4b,7,7,10a-tetramethyl-4ah,5h,6h,6ah,8h,9h,10h,10bh,11h,12h-naphtho[2,1-f]isoquinolin-4a-yl
C26H38NO4 (428.28006880000004)